Tarceva Seeks FDA Approval to Treat Non-Small Cell Lung Cancer

Share Article

On November 20th, 2012 Pharmaceutical Business Review published that Astellas Pharma seeks US FDA approval for its drug Tarceva to treat non-small cell lung cancer patients (NSCLC). Tarceva, sold by Astellas Pharma Inc and Genentech, a unit of Roche Holding, is a drug used to treat patients with unresectable cancer of the lung or of the pancreas that is either spreading locally or has metastasized. In July 2009, the US FDA announced the drug’s label information warning about three kinds of serious adverse events including gastrointestinal perforation, which can be fatal. Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple solutions including how to get in contact with legal counsel so anyone can easily and inexpensively deal with cases of Tarceva severe adverse events. [http://www.attorneyone.com/tarceva-lawsuit/

Tarceva: severe adverse events

Tarceva: severe adverse events

bleeding events, including gastrointestinal and non-gastrointestinal bleeding (including fatalities), have been reported

The media spotlight is often a double-edged sword. No one knows this better than people who filed a Tarceva Lawsuit. And yet, gossip and rumor-mongering aside, the real story here is being overlooked according to Sean Burke of AttorneyOne.

On November 20th, 2012 Pharmaceutical Business Review published that Astellas Pharma seeks US FDA approval for its drug Tarceva to treat non-small cell lung cancer patients (NSCLC) with tumors containing epidermal growth factor receptor (EGFR) that triggers mutations. Tarceva, sold by Astellas Pharma Inc and Genentech, a unit of Roche Holding, is a drug used to treat patients with unresectable cancer of the lung or of the pancreas that is either spreading locally or has metastasized.

In July 2009, the US FDA announced the drug’s label information warning about three kinds of serious adverse events including gastrointestinal perforation, which can be fatal.

AttorneyOne.com, a recognized authority on law, can provide helpful advice and simple solutions including how to get in contact with legal counsel so that, in case of severe complications from Tarceva, someone can easily and inexpensively deal with it. As Mr. Burke, director of Media Relations for AttorneyOne.com, added, “What all this information really illustrates is that threat from Tarceva remains. For that reason, our focus should squarely fall on getting the word out and assisting people in finding the right legal assistance.”

In April 2012, the FDA approved safety label changes for Tarceva tablets which mentioned that International Normalized Ratio (INR) elevations and bleeding events, including gastrointestinal and non-gastrointestinal bleeding (including fatalities), have been reported, associated with concomitant warfarin administration.

AttorneyOne.com has further information on Tarceva lawsuits including how to get in contact with legal counsel.

Headquartered in San Diego, CA Attorney One was founded in 2004 and is not a law firm. They offer a nationwide legal service which helps consumers find the best representation for their legal needs. You can learn more about Attorney One at our website http://www.attorneyone.com. You can also find us on Facebook at http://www.facebook.com/AttorneyOne. Checkout earlier news from us at http://www.prweb.com/releases/2012/11/prweb10163796.htm.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sean Burke
Visit website